Abbisko Cayman Limited (HK:2256) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, presented promising Phase I study results of their oral PD-L1 inhibitor, ABSK043, at the ESMO Asia 2024. The study highlighted ABSK043’s favorable safety and strong anti-tumor activity, particularly in non-small cell lung cancer patients with high PD-L1 expression. This development positions Abbisko as a potential leader in the oral PD-L1 inhibitor market, with further investigations underway.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Weighs in on Robinhood Stock Amid Soaring Trading Volumes
- Paramount Global (NASDAQ:PARA) Deal May Face Risks from Trump Administration
- Ford’s (NYSE:F) Electric Vehicle Motor Production Begins
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
